Latanoprost treatment for glaucoma: Effects of treating for 1 year and of switching from timolol

Carl B. Camras, Martin B. Wax, Robert Ritch, Robert Weinreb, Alan L. Robin, Eve J. Higginbotham, Jacqueline Lustgarten, William C. Stewart, Mark Sherwood, Theodore Krupin, Jacob Wilensky, George A. Cioffi, L. Jay Katz, Robert A. Schumer, Paul L. Kaufman, Don Minckler, Thom Zimmerman, Johan Stjernschantz

Research output: Contribution to journalArticlepeer-review

78 Scopus citations


PURPOSE: To determine the efficacy and safety of latanoprost treatment for 1 year in glaucoma patients, and to evaluate the effects of switching from timolol to latanoprost therapy. METHODS: Latanoprost 0.005% was topically applied once daily without masking for 6 months in 223 patients with elevated intraocular pressure after previous treatment with latanoprost once daily or 0.5% timolol twice daily for 6 months in a multicenter, randomized, double-masked, parallel group study. RESULTS: Compared with baseline values before treatment, a significant (P < .0001) diurnal reduction in intraocular pressure of 6 to 8 mm Hg was maintained with minimal fluctuation for the duration of treatment. When treatment was switched from timolol to latanoprost, intraocular pressure was reduced by 1.5 ± 0.3 mm Hg (mean ± SEM; 8% change in intraocular pressure; 31% of the intraocular pressure reduction produced by timolol; P < .001) compared with the change in intraocular pressure in patients remaining on latanoprost therapy. Of the patients initially enrolled, 95% successfully completed treatment. There was a slight overall increase in conjunctival hyperemia in patients who switched from timolol to latanoprost, but no change in those who continued latanoprost. The timolol-induced reduction of resting heart rate returned to baseline levels after switching to latanoprost. Of the 247 patients treated with latanoprost during the masked and/or open-label studies, 12 (5%) demonstrated a definite (n = 4) or possible (n = 8) increase in iris pigmentation. CONCLUSIONS: Latanoprost is a well-tolerated ocular hypotensive agent that appears to be more effective than timolol in reducing intraocular pressure. The increase in iris pigmentation appears to be harmless but requires further investigation.

Original languageEnglish
Pages (from-to)390-399
Number of pages10
JournalAmerican Journal of Ophthalmology
Issue number3
StatePublished - Sep 1998


Dive into the research topics of 'Latanoprost treatment for glaucoma: Effects of treating for 1 year and of switching from timolol'. Together they form a unique fingerprint.

Cite this